2nd Quarter - Report

KNIGHT CAPITOL CONSULTANTS for INDIVIOR, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$40,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2022 $40,000 Replaced
2nd Quarter - Report Jul 20, 2022 $40,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Mainstreaming Addiction Treatment Act ( HR 1384; S 445); Medication Access and Training Expansion Act, (HR 2067, HR 7667);

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2067 (117th), H.R. 7667 (117th), H.R. 1384 (117th)

Budget/Appropriations BUD

Funding for mental health and substance abuse research and grants; issues related to provisions affecting regulation and pricing of pharmaceuticals in any FY 2034 Labor-HHS appropriations act ( no bill yet)

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

The Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (no specific legislation). Possible changes in reimbursement for pharmaceuticals (HR 3, HR 5376 - Build Back Better Act, and any successor legislation, budget reconciliation legislation ( no bill numbers)

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch (1999-2007)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 955 (117th), H.R. 3 (117th), H.R. 5376 (117th), S. 445 (117th)

Health Issues HCR

Implementation of section 3204 of the SUPPORT Act, PL 115-271; Mainstreaming Addiction Treatment Act (HR 2067, HR 7667); Drug Enforcement Administration regulation of buprenorphine under the Controlled Substances Act. Food and Drug Administration Safety and Landmark Advancement act FDASLA / FDA user fee reauthorization (HR 7667, S 4348; Restoring Hope for Mental Health and Well-Being Act (HR 7666).

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Chief of Staff, Senator Orrin G. Hatch

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2067 (117th), H.R. 7666 (117th), H.R. 7667 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.